Working… Menu

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03785184
Recruitment Status : Withdrawn (Strategic considerations)
First Posted : December 24, 2018
Last Update Posted : August 27, 2019
Genentech, Inc.
Celgene Corporation
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Actual Primary Completion Date : August 22, 2019
Actual Study Completion Date : August 22, 2019